CARMAT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.37 EUR | 0.00% |
|
-5.20% | -64.63% |
| 25/06 | France's Carmat Names New Chairman | MT |
| 25/06 | Carmat: changes in corporate governance | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
11/09/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.37
EUR
Average target price
12.32
EUR
Spread / Average Target
+420.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -64.63% | 87.21M | |
| +13.71% | 130B | |
| -9.24% | 10.77B | |
| -15.31% | 7.37B | |
| +46.76% | 5.87B | |
| -32.21% | 4.1B | |
| +8.24% | 3.44B | |
| -19.53% | 2.47B | |
| -17.06% | 1.94B | |
| -22.28% | 1.72B |
- Stock Market
- Equities
- ALCAR Stock
- News CARMAT
- Euroland Corporate Starts Carmat at Buy
